Literature DB >> 12950465

Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier.

Fanchon Bourasset1, Salvatore Cisternino, Jamal Temsamani, Jean-Michel Scherrmann.   

Abstract

Morphine-6-beta-d-glucuronide (M6G) is an active metabolite of morphine with high analgesic potency despite a low blood-brain barrier (BBB) permeability. The aim of the study was to elucidate its transport mechanism across the BBB. We first checked if M6G was effluxed by the P-glycoprotein (P-gp), as previously reported by others. Second, we investigated the role of anionic transporters like the multidrug resistance-associated protein mrp1 and the glucose transporter GLUT-1. The brain uptake of [14C]M6G was measured by the in situ brain perfusion technique in wild-type and deficient mice [mdr1a(-/-) and mrp1(-/-)], with and without probenecid, digoxin, PSC833 or d-glucose. No difference was found between P-gp and mrp1 competent and deficient mice. The brain uptake of [14C]M6G co-perfused with probenecid in wild-type mice was not significantly different from that found in group perfused with [14C]M6G alone. The co-perfusion of [14C]M6G with digoxin or PSC833 was responsible of a threefold decrease of its uptake in mdr1a competent and deficient mice, suggesting that another transporter than P-gp and sensitive to digoxin and PSC833, may be involved. The co-perfusion of [14C]M6G with d-glucose revealed a threefold decrease in M6G uptake. In conclusion, P-gp and mrp1 are not involved in the transport of M6G at the BBB level in contrast to GLUT-1 and a digoxin-sensitive transporter (probably oatp2), which can actively transport M6G but with a weak capacity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12950465     DOI: 10.1046/j.1471-4159.2003.01990.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  30 in total

Review 1.  Role of morphine's metabolites in analgesia: concepts and controversies.

Authors:  Erica Wittwer; Steven E Kern
Journal:  AAPS J       Date:  2006-05-26       Impact factor: 4.009

Review 2.  Candidate gene polymorphisms predicting individual sensitivity to opioids.

Authors:  Shinya Kasai; Masakazu Hayashida; Ichiro Sora; Kazutaka Ikeda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

Review 3.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

Review 4.  Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance.

Authors:  Susan L Mercer; Andrew Coop
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

5.  Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception.

Authors:  Noam Zelcer; Koen van de Wetering; Michel Hillebrand; Elise Sarton; Annemieke Kuil; Peter R Wielinga; Thomas Tephly; Albert Dahan; Jos H Beijnen; Piet Borst
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-10       Impact factor: 11.205

Review 6.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

7.  The influence of age on the distribution of morphine and morphine-3-glucuronide across the blood-brain barrier in sheep.

Authors:  J Bengtsson; P Ederoth; D Ley; S Hansson; I Amer-Wåhlin; L Hellström-Westas; K Marsál; C-H Nordström; M Hammarlund-Udenaes
Journal:  Br J Pharmacol       Date:  2009-05-11       Impact factor: 8.739

Review 8.  CNS delivery via adsorptive transcytosis.

Authors:  Françoise Hervé; Nicolae Ghinea; Jean-Michel Scherrmann
Journal:  AAPS J       Date:  2008-08-26       Impact factor: 4.009

Review 9.  Pharmacology of morphine in obese patients: clinical implications.

Authors:  Célia Lloret Linares; Xavier Declèves; Jean Michel Oppert; Arnaud Basdevant; Karine Clement; Christophe Bardin; Jean Michel Scherrmann; Jean Pierre Lepine; Jean François Bergmann; Stéphane Mouly
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 10.  Pharmacokinetics and dosage adjustment in patients with renal dysfunction.

Authors:  Roger K Verbeeck; Flora T Musuamba
Journal:  Eur J Clin Pharmacol       Date:  2009-06-20       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.